<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930163</url>
  </required_header>
  <id_info>
    <org_study_id>ILR4646g</org_study_id>
    <nct_id>NCT00930163</nct_id>
  </id_info>
  <brief_title>A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids</brief_title>
  <acronym>MILLY</acronym>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to evaluate the effects of
      lebrikizumab in patients with asthma who remain inadequately controlled while on chronic
      therapy with inhaled corticosteroids (ICS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>From baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pre-bronchodilator FEV1</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life and symptom scores</measure>
    <time_frame>From baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak flow</measure>
    <time_frame>From baseline to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of asthma exacerbations</measure>
    <time_frame>During the 24 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rescue medication use</measure>
    <time_frame>From baseline to Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of human anti-therapeutic antibodies (ATA)</measure>
    <time_frame>At the end of the follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lebrikizumab (MILR1444A)</intervention_name>
    <description>Subcutaneous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subcutaneous repeating dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight 40 kg--150 kg

          -  Chest radiograph with no evidence of clinically significant abnormality

          -  Uncontrolled asthma

        Exclusion Criteria:

          -  Asthma exacerbation during screening

          -  Known malignancy

          -  Known immunodeficiency

          -  Pre-existing lung disease other than asthma

          -  Uncontrolled clinically significant medical disease

          -  Current smoker

          -  History of substance abuse that may impair or risk the patient's full participation in
             the study, in the judgment of the investigator

          -  Prior allergic reaction to a monoclonal antibody

          -  Patients (men and women) of reproductive potential who are not willing to use
             contraception

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Freemer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <disposition_first_submitted>June 30, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 30, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 13, 2011</disposition_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

